The drug company Pfizer says it has started giving its experimental mRNA influenza vaccine to some of the 25,000 adults taking part in stage III clinical trials for the vaccine.
“The flexibility of mRNA technology and its rapid manufacturing could potentially allow better strain matches in future years, and in a pandemic influenza situation, mRNA technology could allow rapid, large-scale manufacturing of vaccines,” Pfizer said in a news release.
“Moderna is proactively preparing for a confirmatory efficacy study for mRNA-1010 as early as the 2022/2023 Northern Hemisphere influenza season, if needed,” the release said. The CDC estimates that the flu resulted in 12,000 to 52,000 deaths and 140,000 to 710,000 hospitalizations each year between 2010 and 2020, with a greater impact on racial and ethnic minority groups.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Penalties rolled back for Marines seeking COVID-19 vaccine exceptionsThe Marine Corps has rescinded some penalties placed on service members who have sought a religious exemption from a requirement to get the COVID-19 vaccination, such as promotion delays and administrative separations.
Lire la suite »
Your Questions about the New COVID Booster Shots, AnsweredNew COVID booster vaccines built for the latest variants are here and should be more effective. But there are still some unknowns
Lire la suite »
COVID deaths: more than 10 million children lost a parent or carerThe consequences of losing a parent can be profound, but the right support can reduce the impact.
Lire la suite »
New York state shuts down COVID-19 data tracker for schoolsConcerned New York City parents noticed this week that a tracker for COVID-19 data across state schools now redirects to the New York State Department of Health’s main page on its COVID-19 response.
Lire la suite »